Use of rivaroxaban in the prevention of cerebrovascular accident in a patient with chronic heart failure and nonvalvular atrial fibrillation – a case study

Authors: F. Málek;  D. Vondráková;  J. Škoda;  P. Neužil
Authors‘ workplace: Ambulance srdečního selhání a hypertenze, Kardiocentrum, Nemocnice Na Homolce, Praha
Published in: Kardiol Rev Int Med 2016, 18(2): 130-132


Rivaroxaban is a direct oral factor Xa inhibitor indicated for prevention of stroke in patients with nonvalvular atrial fibrillation. A real-life case study shows the use of rivaroxaban in primary prevention of stroke in a patient with chronic heart failure and high risk of a thromboembolic event and a moderate risk of bleed­ing. The case report emphasises the need of repeated laboratory examinations in such vulnerable patients with monitoring of renal parameters during cardiac decompensation episodes.

nonvalvular atrial fibrillation – heart failure – renal function – anticoagulation therapy – rivaroxaban


1. Patel MR, Mahaffey KW, Garg J et al. The ROCKET- AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New J Engl Med 2011; 365: 883– 891. doi: 10.1056/ NEJMoa1009638.

2. Špinar J, Vítovec J. Studie ROCKET-AF –  konec warfarinu na obzoru? Kardiol Rev Int Med 2011; 13: 106– 108.

3. Karetová D, Bultas J. Nová perorální an­ti­trom­botika v prevenci a léčbě trombembolizmu. Kardiol Rev Int Med 2012; 14: 88– 92.

4. Cleland JG. Anticoagulant and antiplatelet therapy in heart failure. Curr Opin Cardiol 1997; 12: 276– 287.

5. Diet F, Erdmann E. Thromboembolism in heart fail­ure: who should be treated? Eur J Heart Fail 2000; 2: 355– 363.

6. Dries DL, Rosenberg YD, Waclawiw MA et al. Ejection fraction and risk of thromboembolitic events in patients with systolic dysfunction and sinus rhythm. J Am Coll Cardiol 1997; 29: 1074– 1080.

7. Howell MD, Geraci JM, Knowlton AA. Congestive heart failure and outpatient risk of venous tromboembolism: a retrospective, case-control study. J Clin Epidemiol 2001; 54: 810– 816.

8. Pisters R, Lane DA, Nieuwlaat R et al. A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: The Euro Heart Survey. Chest 2010; 138: 1093– 1100. doi: 10.1378/ chest.10-0134.

9. Roldán V, Marín F, Fernández H et al. Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a "real-world" population with atrial fibrillation receiving anticoagulant therapy. Chest 2013; 143: 179– 184.

Paediatric cardiology Internal medicine Cardiac surgery Cardiology
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.


Don‘t have an account?  Create new account